Evidence-based Pain Management: Addressing the Growing Role of Nurse Practitioners and Physician Assistants in Managing Patients with Acute and Chronic Pain

Format: Webinar
Credit(s): 3.00 (3 hrs)
Webinar Date(s):
07/15/2020 at 6:00 – 9:00 PM ET
Credit Type(s):
  • CME / AMA PRA Category 1 Credit™


Tuesday, June 16, 2020
4:00 – 7:00 PM ET (3:00 – 6:00 PM CST / 1:00 – 4:00 PM PST)
Program Faculty: Christopher Gharibo, MD; Susan Pendergrass, MSN, MEd, APRN, FNP-BC

Wednesday, July 15, 2020
6:00 – 9:00 PM ET (5:00 – 8:00 PM CST / 3:00 – 6:00 PM PST)
Program Faculty: Jeremy A. Adler, DMSc, PA-C; Christopher Gharibo, MD

Primary care providers (PCPs) are responsible for almost half of all opioid prescriptions written in the US, and a recent study found that primary care NPs and PAs wrote more opioid prescriptions than their physician colleagues. However, limited time, training, and access to resources often make it difficult for these clinicians to effectively evaluate their patients presenting with pain and choose a treatment that best fits each patient’s needs.

This CME activity, Evidence-based Pain Management: Addressing the Growing Role of Nurse Practitioners and Physician Assistants in Managing Patients with Acute and Chronic Pain, will help community NPs and PAs use pain-assessment tools to evaluate patients, improve their familiarity with the FDA Blueprint guidelines for treatment selection, and understand when to use non-opioid pharmacotherapies for neuropathic pain.


Welcome and Introduction
The need for pain education
Mechanisms of pain and definitions
Assessment and risk stratification of patient in pain
Components of an effective treatment plan
Non-pharmacologic, pharmacologic and alternative therapeutic options for pain
Managing patients on opioid analgesics
Assessing risk of and management of opioid use disorder
Q&A and Concluding Remarks


This activity is intended for is clinicians involved in direct patient care, including HCPs who are registered with the DEA and eligible to prescribe all opioid analgesics. In addition, because of the broad scope of the revised FDA blueprint, the intended audience may include members of the healthcare team without authorization to prescribe.

Specifically, this education will be targeted to NPs and PAs who need to improve their ability to obtain a balance between optimal pain reduction and minimization of adverse events (e.g. abuse, addiction, side effects, and risk of workplace accidents).


At the conclusion of this activity, participants should be able to:

  • Incorporate tools to assist in assessing pain, stratifying risks
  • Evaluate components of effective treatment plan: acute vs chronic pain, treatment goals, multimodal strategies
  • Make evidence-based treatment plan recommendations: non-/pharmacologic and alternative therapies
  • When considering opioid therapy, assess potential for abuse and evidence-based monitoring
  • Discuss evidence-based options for opioid use disorder: physician-patient counseling, local/national/online resources



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of USF Health and Rockpointe. USF Health is accredited by the ACCME to provide continuing medical education for physicians.



USF Health designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email: cpdsupport@usf.edu.


Jeremy A. Adler, DMSc, PA-C
Pain Management PA/COO
Pacific Pain Medicine Consultants
Oceanside, CA
Christopher Gharibo, MD
Medical Director of Pain Medicine
NYU Langone Health
Associate Professor of Anesthesiology, Pain Medicine and Orthopedics
New York, NY
Susan Pendergrass, MSN, MEd, APRN, FNP-BC
Nurse Practitioner
Independent Pain Consultant
Fernandina Beach, FL
Aaron Williams, MA
Senior Director of Training and TA for Substance Use
National Council for Behavioral Health
Washington, DC


This education activity is pending approval by the American Association of Nurse Practitioners of up to 3.0 contact hour of accredited education.


This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 3 AAPA Category 1 CME credits. Approval is valid from 6/15/2020 to 6/15/2021 . PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-200578.


USF Health endorses the standards of the ACCME that require everyone in a position to control the content of an accredited educational activity to disclose all financial relationships with commercial interests that are related to the content of the educational activity. All accredited activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when individuals in a position to control the content of an accredited educational activity have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. USF Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Faculty and Steering Committee Disclosures
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Jeremy Adler, DMSc, PA-C: Advisory Board: BioDelivery Sciences International, US WorldMeds; Speaker’s Bureau: BioDelivery Sciences International, Daiichi Sankyo, Pfizer, Scilex

Christopher Gharibo, MD: Consultant: Averitas, DSI, Persion, Salix; Speaker’s Bureau: Scilex

Susan Pendergrass, MSN, Med, APRN, FNP-BC: Advisory Board: Johnson & Johnson, Pear Therapeutics; Consultant/Speaker’s Bureau: Johnson & Johnson

Aaron Williams, MA: Nothing to disclose

Non-faculty Disclosures
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Martin Myers, MD: Advisory Board: Amgen

Chad Williamson, MS, MBA, CMMP; USF Health CPD staff: Nothing to disclose


The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.


USF Health is an Equal Opportunity/ Affirmative Action/ Equal Access Institution.


USF Health does not endorse any product, material, or service mentioned in association with this activity.


The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.


To ensure your computer is compatible for the live event, please perform a system check by clicking on the link http://livewebcast.net/test or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.


There is no fee for this activity. To receive credit, participants must register, view the live activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is 3 hours. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.


Jointly provided by USF Health and Rockpointe

  Physician CME


In collaboration with


This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see
https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA).


Breakthroughs with NASH Management: What Do Gastroenterologists and Hepatologists Need to Know?

Learn More

Management of Neovascular Age-Related Macular Degeneration: Improving Patient Outcomes

Learn More

Eosinophilic Granulomatosis with Polyangiitis: Where Are We with Diagnosis and Management?

Learn More
This entry was posted in . Bookmark the permalink.

Follow Us :

Follow Us :

© 2021 Rockpointe Corporation

Privacy Policy

© 2021 Rockpointe Corporation

Privacy Policy